AMPE Ampio Pharmaceuticals Inc.

1.15
+0.16  (16%)
Previous Close 0.99
Open 1.04
Price To book 23.00
Market Cap 78467270
Shares 68,232,409
Volume 2,821,012
Short Ratio 16.03
Av. Daily Volume 514,899

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171140987
  2. 8-K - Current report 171137773
  3. 8-K - Current report 171104314
  4. 8-K - Current report 171096678
  5. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 171074449

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

STRIDE study mid April 2015 did not meet endpoint. Second Phase 3 trial also did not meet primary endpoint - June 2016. Futher trial initiation announced June 22, 2017.
Ampion
Osteoarthritis of the Knee
Phase 2b data released May 2015 did not meet endpoints
Optina
Diabetic Macula Edema

Latest News

  1. Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering
  2. Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering
  3. Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Ardelyx Inc.
  4. Ampio Announces Accepted Publication of Pooled Ampion™ Clinical Trial Results in Patients with Severe Osteoarthritis of the Knee
  5. Ampio Completes Enrollment of Patients in 12-Week Pivotal Trial
  6. Ampio Pharmaceuticals, Inc. Announces Annual Shareholder Meeting
  7. Ampio Pharmaceuticals, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
  8. Ampio Discloses Receipt of Notice from NYSE American and Has Until March 1, 2019, to Gain Compliance
  9. Ampio Announces the Allowance of a Composition and Methods Patent in the USA Using Ampion™ in Conjunction with Stem Cells
  10. Ampio Hosting Conference Call, Wednesday, July 12, 4:30 pm EDT
  11. Ampio Injects First Patient in Final Pivotal Clinical Trial for Ampion™ BLA
  12. Ampio Announces Appointment of Interim Chief Financial Officer
  13. Ampion™ Human Macrophage Study Results Accepted for Presentation at the 2017 Annual AAST Meeting in Baltimore
  14. Ampio Initiates Pivotal Trial of Ampion™
  15. Ampio Pharmaceuticals Amends Warrant Agreement
  16. Ampio Updates Intellectual Property and Regulatory Exclusivity Strategy to Support the Commercialization of Ampion™

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171140987
  2. 8-K - Current report 171137773
  3. 8-K - Current report 171104314
  4. 8-K - Current report 171096678
  5. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 171074449
  6. 8-K - Current report 171074190
  7. 8-K - Current report 171058493
  8. DEF 14A - Other definitive proxy statements 171056598
  9. PRE 14A - Other preliminary proxy statements 171041756
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016342